AzTrials
AzTrials

InfertilityNCT02365350

Randomized Clinical Trial on Follicular Flushing in IVF

A study testing STEINER-TAN Needle® and 17 G single lumen needle in people with Infertility, run by University of Luebeck at 1 site in Germany.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective is to demonstrate superiority of follicle flushing with the STEINER-TAN Needle® as compared to single lumen aspiration in terms of numbers of COCs retrieved. Read more about this study

Who is it for?
Ages 18 to 45 years, women only
Conditions the study is for
Infertility
What is being tested?
STEINER-TAN Needle® and 17 G single lumen needle
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteGermany
Study dates
Jan 2015to Aug 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Female subjects undergoing IVF or ICSI treatment with or without ovarian stimulation
  • ≤ 5 follicles >10 mm at the end of the follicular phase as assessed by transvaginal ultrasound
  • Presence of two ovaries
  • Willingness to participate
  • Informed consent

Who cannot join

  • BMI <18 or >35 kg/m2
  • Ovaries cannot be reached (e.g. heterotopic ovaries)
  • Age <18 or >45

Trial locations and contacts

1 site in 1 country.

Germany1 site
  • Universitäres Kinderwunschzentrum Lübeck

    Lübeck, Schleswig-Holstein, 23562

Other trials in Germany

About this study

Official title: A Randomized, Controlled, Open Trial Comparing a 17 G Single Lumen Aspiration Needle With a Modified Double Lumen Needle System (STEINER-TAN Needle®) for Follicular Flushing During Oocyte Pick-up in IVF Patients With Poor Ovarian Response

The primary objective is to demonstrate superiority of follicle flushing with the STEINER-TAN Needle® as compared to single lumen aspiration in terms of numbers of COCs retrieved.

Read the detailed description

Rationale:

Since the number of oocytes available for IVF is a determinant of the cumulative chance of a patient to achieve pregnancy, it is of paramount importance to optimize the number of oocytes at oocyte pick-up. This especially for a fraction of patients, who despite high-dosed FSH stimulation, produce only a small number of growing follicles (poor response).

Objective:

The primary objective is to demonstrate superiority of follicle flushing with the STEINER-TAN Needle® as compared to single lumen aspiration in terms of numbers of COCs retrieved.

The secondary objective is to study differences in numbers of mature oocytes, proportion of patients undergoing embryo transfer, pregnancy rate, duration of the procedure, impact on patient burden (as assessed by the DASS 21, the German pain questionnaire [www.dgss.org]) and subjective patient experience.

Study design:

Prospective, single-center, randomized controlled, open trial comparing a 17G single lumen aspiration needle with a modified double lumen needle system (STEINER-TAN Needle®) for follicular flushing during oocyte pick-up in IVF patients with poor ovarian response.

Study population:

Patients with a BMI < 35 kg/m2 and an indication for IVF or ICSI with or without ovarian stimulation presenting with ≤ 5 follicles >10mm in the ovaries at the end of the follicular phase of the treatment cycle will be eligible for inclusion. Final oocyte maturation is to be induced by hCG administration as soon as the leading follicle reaches a mean diameter of 18mm or the day thereafter.

Intervention:

Eighty (n=80) patients will be randomly allocated on the day when the decision is taken to administer hCG to one of the following two procedures. In the study group all visible follicles regardless of size in both ovaries will be first aspirated and then flushed at least three times by the STEINER-TAN Needle® system. In the control group all visible follicles regardless of size in both ovaries will be aspirated by the 17G single lumen needle.

Main study parameters/endpoints:

The main study parameter/endpoint is the mean number of COSs per patient randomized.

Secondary endpoints are the mean number of mature metaphase II oocytes per patient and per COC retrieved per patient, the number of fertilized (2PN) oocytes, the fertilization rate (number of 2PN oocytes/number of injected or inseminates oocytes), the pregnancy rate (viable pregnancy at 6-7 gestational weeks/randomized patient), the mean DASS 21 score after the procedure, the mean duration of the procedure (min, sec), the COC retrieval rate per puncture follicle and the proportion of randomized patients not reaching embryo transfer. Furthermore, the patients will be interviewed about their overall experience of the procedure.

Conditions
Infertility
Being tested
STEINER-TAN Needle®, 17 G single lumen needle
Medical subject headings
Infertility

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • STEINER-TAN Needle®Procedure or surgery

    A purpose built new double lumen needle with little dead space.

  • 17 G single lumen needleProcedure or surgery

    A conventional single lumen IVF aspiration needle.

Study groups in NCT02365350
Study groupRoleWhat they receive
STEINER-TAN Needle®ExperimentalAll visible follicles regardless of size in both ovaries will be aspirated and flushed three times by the STEINER-TAN Needle.
Receives: Procedure: STEINER-TAN Needle®
17G single lumen needleActive comparatorIn the control group all visible follicles regardless of size in both ovaries will be aspirated by the 17G single lumen needle.
Receives: Procedure: 17 G single lumen needle

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean number of COSs per patient randomized.

    Measured: 1 day

Secondary outcomes (5)
  1. Mean number of mature metaphase II oocytes

    Measured: 1 day

  2. Pregnancy rate

    Measured: 7 weeks

  3. Mean number of fertilized (2PN) oocytes

    Measured: 2 days

  4. Mean DASS 21 score after the procedure

    Measured: 1 day

  5. Mean duration of the procedure.

    Measured: 1 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Feb 2015 (estimated)
  2. Study startJan 2015
  3. Primary completionAug 2016
  4. Study completionAug 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02365350
Sponsor's protocol ID
14-244
Status last verified
Nov 2016
First submitted
6 Feb 2015
Last updated
18 Nov 2016
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing STEINER-TAN Needle® and 17 G single lumen needle in people with Infertility, run by University of Luebeck at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Nov 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean number of COSs per patient randomized. (time frame: 1 day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in